RU2529797C2 - Раковый маркер и терапевтическая мишень - Google Patents

Раковый маркер и терапевтическая мишень Download PDF

Info

Publication number
RU2529797C2
RU2529797C2 RU2010123921/15A RU2010123921A RU2529797C2 RU 2529797 C2 RU2529797 C2 RU 2529797C2 RU 2010123921/15 A RU2010123921/15 A RU 2010123921/15A RU 2010123921 A RU2010123921 A RU 2010123921A RU 2529797 C2 RU2529797 C2 RU 2529797C2
Authority
RU
Russia
Prior art keywords
tumor
ccr4
cells
cancer
solid tumor
Prior art date
Application number
RU2010123921/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010123921A (ru
Inventor
Фрэнсис БЭЛКВИЛЛ
Вайолет СЛЭТТЕНААР
Джулия УИЛСОН
Яохэ ВАН
Тициана СКЬОППА
Original Assignee
Кэнсер Рисёч Текнолоджи Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2529797(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Кэнсер Рисёч Текнолоджи Лтд filed Critical Кэнсер Рисёч Текнолоджи Лтд
Publication of RU2010123921A publication Critical patent/RU2010123921A/ru
Application granted granted Critical
Publication of RU2529797C2 publication Critical patent/RU2529797C2/ru

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
RU2010123921/15A 2007-09-18 2008-09-18 Раковый маркер и терапевтическая мишень RU2529797C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0718167.0 2007-09-18
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
PCT/GB2008/003160 WO2009037454A2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2014128513A Division RU2014128513A (ru) 2007-09-18 2014-07-14 Раковый маркер и терапевтическая мишень

Publications (2)

Publication Number Publication Date
RU2010123921A RU2010123921A (ru) 2011-12-20
RU2529797C2 true RU2529797C2 (ru) 2014-09-27

Family

ID=38670078

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010123921/15A RU2529797C2 (ru) 2007-09-18 2008-09-18 Раковый маркер и терапевтическая мишень
RU2014128513A RU2014128513A (ru) 2007-09-18 2014-07-14 Раковый маркер и терапевтическая мишень

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014128513A RU2014128513A (ru) 2007-09-18 2014-07-14 Раковый маркер и терапевтическая мишень

Country Status (11)

Country Link
US (2) US9134293B2 (enExample)
EP (3) EP2535716B1 (enExample)
JP (2) JP5774309B2 (enExample)
AU (1) AU2008300413B2 (enExample)
CA (1) CA2699702C (enExample)
DK (3) DK2533047T3 (enExample)
ES (3) ES2443541T3 (enExample)
GB (1) GB0718167D0 (enExample)
PL (3) PL2535716T3 (enExample)
RU (2) RU2529797C2 (enExample)
WO (1) WO2009037454A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180125970A1 (en) * 2015-04-17 2018-05-10 Morphotek, Inc. Methods for treating lung cancer
RU2740254C2 (ru) * 2014-10-01 2021-01-12 Сфинготек Гмбх ОПРЕДЕЛЕНИЕ hGH ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ТЯЖЕЛОГО НЕБЛАГОПРИЯТНОГО СЕРДЕЧНО-СОСУДИСТОГО ЯВЛЕНИЯ ИЛИ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ У ИНДИВИДУУМА

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
EP2580348B1 (en) * 2010-06-14 2018-04-25 Qiagen GmbH Method for determination of target cells or tissue for extraction of biomolecules from non-formalin-fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
HK1212389A1 (en) 2011-10-24 2016-06-10 Signalchem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
JP6141864B2 (ja) 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
PL3065774T3 (pl) * 2013-11-06 2021-12-13 Janssen Biotech, Inc Przeciwciała anty-ccl17
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
EP3329244B1 (en) 2015-07-30 2022-10-05 Qiagen GmbH Method of preparing a frozen biological sample
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
JP7177445B2 (ja) * 2017-05-19 2022-11-24 真吾 前田 Ｃｃｒ４阻害による制御性ｔ細胞浸潤抑制法およびイヌの腫瘍性疾患の治療法
ES3064498T3 (enExample) 2018-08-29 2026-04-27 Chemocentryx Inc
EP3885452A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on chemokine genes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042074A1 (en) * 1999-01-15 2000-07-20 Millennium Pharmaceuticals, Inc. Anti-ccr4 antibodies and methods of use therefor
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
US20070149449A1 (en) * 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
WO1994021814A1 (en) * 1993-03-19 1994-09-29 The Johns Hopkins University Antibodies and assays for determining mutations in the apc gene
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
WO2001064754A1 (en) 2000-03-03 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Gene recombinant antibody and its fragment
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
US20020173524A1 (en) 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
AU2002223619B2 (en) 2000-10-18 2006-08-24 Schering Ag Use of antiprogestins for the induction of apoptosis in a cell
MXPA03007681A (es) * 2001-02-28 2004-11-12 Protein Design Labs Inc Receptores para quimiocinas y enfermedades.
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
CA2456928A1 (en) 2001-08-10 2003-02-20 Topigen Pharmaceutique Inc. Cellular virus receptors and methods of use
MXPA04001894A (es) 2001-08-31 2005-09-08 Kyowa Hakko Kogyo Kk Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo.
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
EP1688436A4 (en) * 2003-10-08 2009-12-02 Kyowa Hakko Kirin Co Ltd ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY
DE602004029934D1 (de) 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP1984501B1 (en) 2006-02-14 2011-05-18 Noxxon Pharma AG Mcp-i binding nucleic acids
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042074A1 (en) * 1999-01-15 2000-07-20 Millennium Pharmaceuticals, Inc. Anti-ccr4 antibodies and methods of use therefor
US20070149449A1 (en) * 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nakanishi T. Et al. Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer. Cancer Immunol Immunother. 2006 Nov; 55(11), pp.1320-1329. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2740254C2 (ru) * 2014-10-01 2021-01-12 Сфинготек Гмбх ОПРЕДЕЛЕНИЕ hGH ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ТЯЖЕЛОГО НЕБЛАГОПРИЯТНОГО СЕРДЕЧНО-СОСУДИСТОГО ЯВЛЕНИЯ ИЛИ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ У ИНДИВИДУУМА
US20180125970A1 (en) * 2015-04-17 2018-05-10 Morphotek, Inc. Methods for treating lung cancer
RU2718780C2 (ru) * 2015-04-17 2020-04-14 Эйсай Инк. Способы лечения рака легкого
RU2718780C9 (ru) * 2015-04-17 2020-07-08 Эйсай Инк. Способы лечения рака легкого

Also Published As

Publication number Publication date
ES2612690T3 (es) 2017-05-18
EP2176664A2 (en) 2010-04-21
RU2010123921A (ru) 2011-12-20
GB0718167D0 (en) 2007-10-31
WO2009037454A2 (en) 2009-03-26
DK2535716T3 (en) 2017-02-13
EP2533047B1 (en) 2016-05-11
DK2176664T3 (da) 2014-01-20
US20100278844A1 (en) 2010-11-04
US9134293B2 (en) 2015-09-15
US10261099B2 (en) 2019-04-16
RU2014128513A (ru) 2016-02-10
EP2176664B1 (en) 2013-11-06
ES2588507T3 (es) 2016-11-03
JP5774309B2 (ja) 2015-09-09
CA2699702C (en) 2018-03-06
PL2533047T3 (pl) 2016-11-30
EP2535716A2 (en) 2012-12-19
WO2009037454A3 (en) 2009-05-07
AU2008300413A1 (en) 2009-03-26
EP2535716A3 (en) 2013-03-13
JP6234967B2 (ja) 2017-11-22
EP2533047A1 (en) 2012-12-12
JP2015212703A (ja) 2015-11-26
JP2010539508A (ja) 2010-12-16
EP2535716B1 (en) 2016-11-02
CA2699702A1 (en) 2009-03-26
PL2176664T3 (pl) 2014-04-30
ES2443541T3 (es) 2014-02-19
US20160223572A1 (en) 2016-08-04
PL2535716T3 (pl) 2017-06-30
AU2008300413B2 (en) 2014-09-11
DK2533047T3 (en) 2016-08-22

Similar Documents

Publication Publication Date Title
US10261099B2 (en) Cancer marker and therapeutic target
Charpin et al. Quantitative immuno cytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators
Zhao et al. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
Agaimy et al. HMGA2-WIF1 rearrangements characterize a distinctive subset of salivary pleomorphic adenomas with prominent trabecular (canalicular adenoma-like) morphology
EP1565581B1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
CN102667484A (zh) 识别黑素瘤肿瘤细胞的生物标记
US9110064B2 (en) Methods for diagnosis and treatment of endometrial cancer
JP2016522879A (ja) レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
Wang et al. Overexpression of caveolin-1 in cancer-associated fibroblasts predicts good outcome in breast cancer
JP2020040959A (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
EP2457089B1 (en) A method of diagnosing cancer
CN116137862A (zh) 三级淋巴结构在预后疾病进展和治疗癌症中的应用
AU2013203349B2 (en) Cancer marker and therapeutic target
JP5145549B2 (ja) 腫瘍マーカー
JP6306124B2 (ja) 結核検査用バイオマーカー
Pagano The potential role of CXCR4 and SDF-1 as indicators of tumor aggressiviness in patients with conventional papillary thyroid carcinoma

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160919